GlaxoSmithKline in China bribery probe
11 Jul, 2013
Global Healthcare giant, GlaxoSmithKline (GSK), is facing in investigation into alleged bribery carried out by senior executives within the Chinese arm of the company.
The accusations include the offering of bribes to boost sales.
According to the BBC, a GSK spokesman said: “We are investigating these new claims. However, our inquiries to date have found no evidence of bribery or corruption in relation to our sales and marketing of therapeutic Botox in China.
“GSK has some of the toughest compliance procedures in the sector. We are proud of our high standards and operate in accordance with them.”